Cargando…

Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes

PURPOSE: Since ticagrelor inhibits the cellular uptake of adenosine, thereby increasing extracellular adenosine concentration and biological activity, we hypothesized that ticagrelor has adenosine-dependent antiplatelet properties. In the current study, we compared the effects of ticagrelor and pras...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wadowski, Patricia P., Weikert, Constantin, Pultar, Joseph, Lee, Silvia, Eichelberger, Beate, Koppensteiner, Renate, Lang, Irene M., Panzer, Simon, Gremmel, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093367/ https://www.ncbi.nlm.nih.gov/pubmed/32062795 http://dx.doi.org/10.1007/s10557-019-06932-7

Ejemplares similares

Protease‐activated receptor‐mediated platelet aggregation in acute coronary syndrome patients on potent P2Y(12) inhibitors
por: Wadowski, Patricia P., et al.
Publicado: (2019)

Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors
por: Wadowski, Patricia P., et al.
Publicado: (2020)

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
por: Tscharre, Maximilian, et al.
Publicado: (2020)

Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy
por: Wadowski, Patricia P., et al.
Publicado: (2017)

Growth Differentiation Factor 15 Is Associated with Platelet Reactivity in Patients with Acute Coronary Syndrome
por: Mutschlechner, David, et al.
Publicado: (2023)

Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia
por: Lee, Silvia, et al.
Publicado: (2020)

Interleukin-6 and Asymmetric Dimethylarginine Are Associated with Platelet Activation after Percutaneous Angioplasty with Stent Implantation
por: Gremmel, Thomas, et al.
Publicado: (2015)

Growth Differentiation Factor-15 Correlates Inversely with Protease-Activated Receptor-1-Mediated Platelet Reactivity in Patients with Left Ventricular Assist Devices
por: Tscharre, Maximilian, et al.
Publicado: (2022)

Protease‐activated receptor‐mediated platelet aggregation in patients with type 2 diabetes on potent P2Y (12) inhibitors
por: Panzer, Benjamin, et al.
Publicado: (2022)

Functional capillary impairment in patients with ventricular assist devices
por: Wadowski, Patricia P., et al.
Publicado: (2019)

Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy
por: Gremmel, Thomas, et al.
Publicado: (2015)

Toll-like Receptors as Pro-Thrombotic Drivers in Viral Infections: A Narrative Review
por: Panzer, Benjamin, et al.
Publicado: (2023)

Microvascular Thrombosis as a Critical Factor in Severe COVID-19
por: Wadowski, Patricia P., et al.
Publicado: (2023)

Plasma Levels of snoRNAs are Associated with Platelet Activation in Patients with Peripheral Artery Disease
por: Nossent, Anne Yaël, et al.
Publicado: (2019)

Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting
por: Stojkovic, Stefan, et al.
Publicado: (2020)

Platelet-to-lymphocyte and Neutrophil-to-lymphocyte Ratios Predict Target Vessel Restenosis after Infrainguinal Angioplasty with Stent Implantation
por: Lee, Silvia, et al.
Publicado: (2020)

Glycocalyx as Possible Limiting Factor in COVID-19
por: Wadowski, Patricia P., et al.
Publicado: (2021)

α-Hydroxybutyrate dehydrogenase is associated with atherothrombotic events following infrainguinal angioplasty and stenting
por: Lee, Silvia, et al.
Publicado: (2019)

Micro- and Macrovascular Effects of Inflammation in Peripheral Artery Disease—Pathophysiology and Translational Therapeutic Approaches
por: Poledniczek, Michael, et al.
Publicado: (2023)

Acute Limb Ischemia after Intake of the Phenylethylamine Derivate NBOMe
por: Wadowski, Patricia P., et al.
Publicado: (2019)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020)

Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2019)

Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes
por: Ndrepepa, Gjin, et al.
Publicado: (2021)

Surrogate Markers of Neutrophil Extracellular Trap Formation are Associated with Ischemic Outcomes and Platelet Activation after Peripheral Angioplasty and Stenting
por: Demyanets, Svitlana, et al.
Publicado: (2020)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
por: Dai, Lulu, et al.
Publicado: (2022)

Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
por: Koch, Tobias, et al.
Publicado: (2023)

Ticagrelor – toward more efficient platelet inhibition and beyond
por: Kubisa, Michał J, et al.
Publicado: (2018)

Adrenaline enhances in vitro platelet activation and aggregation in blood samples from ticagrelor‐treated patients
por: Singh, Sukhi, et al.
Publicado: (2018)

Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial
por: Baos, Sarah, et al.
Publicado: (2017)

Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis
por: Wen, Mingxiang, et al.
Publicado: (2020)

Metabolism of ticagrelor in patients with acute coronary syndromes
por: Adamski, Piotr, et al.
Publicado: (2018)

Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
por: Lomakin, Nikita, et al.
Publicado: (2019)

Temporal Variability of Platelet Reactivity in Patients Treated with Clopidogrel or Ticagrelor
por: Yun, Kyeong Ho, et al.
Publicado: (2019)

Comparison of ticagrelor and clopidogrel on platelet function and prognosis in unstable angina
por: Li, Chun, et al.
Publicado: (2022)

Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume
por: Zhang, Yang, et al.
Publicado: (2021)

Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
por: Åstrand, Magnus, et al.
Publicado: (2018)

Species Differences in Platelet Protease-Activated Receptors
por: Renna, Stephanie A., et al.
Publicado: (2023)

Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers
por: Traby, Ludwig, et al.
Publicado: (2019)

P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets
por: Gasecka, Aleksandra, et al.
Publicado: (2020)

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_t534ste4ok030famkandnqci3g